Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences
THOUSAND OAKS, Calif., Nov. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday, Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018, in Boston. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conferences. Live audio of each presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of each webcast will also be available on Amgen's website for at least 90 days following the eve...
Source: Amgen News Release - November 21, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO ® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease Application Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative CD19 pos...
Source: Amgen News Release - November 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha ® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Additional Data Analyzing Treatment Patterns in the United States Shows Underutilization of LDL-C Lowering Treatments in At-Risk Patients and Need for Improved Patient Awareness of Treatment Goals THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha® (evolocumab) was associated with robust and consistent reductions in low-density lipoprotein cholesterol (LDL-C), with no increase in overall rates of adverse events over time and no neutralizing ant...
Source: Amgen News Release - November 12, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires
New Pledge is in Addition to $250,000 Contribution to Ventura County Community Foundation's Conejo Valley Victims Fund THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the local wildfires in Ventura and Los Angeles Counties. The Amgen Foundation will select recipient non-profit organizations based on relief effort needs. In addition, the Amgen Foundation has committed $250,000 to the Ventura County Community Foundation's Conejo Valley Victims Fund to support the victims, families and organizations providing su...
Source: Amgen News Release - November 12, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha ® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Additional Analyses of Real-World Data Will Explore Treatment Utilization and Understanding of Treatment Goals in Patients at High Risk for Cardiovascular Events THOUSAND OAKS, Calif., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating the long-term safety and efficacy of Repatha® (evolocumab) in patients with hypercholesterolemia for up to five years. Additional abstracts to be presented include a sub-analysis of the Repatha cardiovascular outcomes study (FOURIER), investigating the effect...
Source: Amgen News Release - November 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714 Amgen Will Invest $20 Million in Provention Equity Amgen Will be Responsible for Clinical Trial Supply and Manufacturing THOUSAND OAKS, Calif. and OLDWICK, N.J., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free di...
Source: Amgen News Release - November 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies BLINCYTO® (blinatumomab) Long-Term Data Demonstrate Benefits of Achieving Complete MRD Response in Adult Patients With Acute Lymphoblastic Leukemia and Reinforce BiTE® Proof-of-Concept Data From Multiple Myeloma Research Foundation CoMMpass Trial of KYPROLIS® (carfilzomib) in Newly Diagnosed Multiple Myeloma Patients to be Presented at ASH THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that ...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program
Through a new $21 Million, Four-Year Investment, Amgen Scholars Program to Reach Additional 1,500 Undergraduates Nearly 4,000 Undergraduates From More Than 700 Colleges and Universities Have Participated to Date Alumni Pursuing Advanced Scientific Degrees and Careers Across the U.S. and Globe THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new four-year, $21 million commitment brings the progr...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Third Quarter 2018 Financial Results
THOUSAND OAKS, Calif., Oct. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include: Total revenues increased 2 percent versus the third quarter of 2017 to $5.9 billion. Product sales grew 1 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth. GAAP earnings per share (EPS) increased 4 percent to $2.86 driven by higher total revenues, a lower tax rate and lower weighted-average shares outstanding. ...
Source: Amgen News Release - October 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha ® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
Repatha Results in Consistent Reductions in LDL-C Levels and Cardiovascular Events in Patients Independent of Kidney Function Results Presented at American Society of Nephrology Kidney Week 2018 THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha® (evolocumab) in patients with established cardiovascular disease by kidney function. In line with previous FOURIER subgroup analyses, these results further demonstrate Repatha's efficacy in reducing not only low-density lipoprotein choleste...
Source: Amgen News Release - October 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast Of 2018 Third Quarter Financial Results
THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2018 financial results on Tuesday, Oct. 30, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and...
Source: Amgen News Release - October 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Makes Repatha ® (Evolocumab) Available In The US At A 60 Percent Reduced List Price
New Option Will Lower Out-of-Pocket Costs for America's Seniors at Risk for Heart Attacks and Strokes THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year. This 60 percent reduction from the medicine's original list price will improve affordability by lowering patient copays, especially for Medicare patients. To view the Multimedia News Release, go to: https://www.multivu.com/...
Source: Amgen News Release - October 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL ® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Results From Head-To-Head Phase 3 SEAM-PsA Study Assessing ENBREL and Methotrexate Regimens in Patients With Psoriatic Arthritis Presented at 2018 ACR/ARHP Annual Meeting Additional Phase 3b Results Show Modified ENBREL Formulation Associated With Significantly Lower Mean Injection Site Pain Versus Prior Formulation Data Presentations Result of Continued Dedication to Evaluate Optimal Use of ENBREL THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL plus ...
Source: Amgen News Release - October 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2018 Fourth Quarter Dividend
THOUSAND OAKS, Calif., Oct. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018. The dividend will be paid on Dec. 7, 2018, to all stockholders of record as of the close of business on Nov. 16, 2018. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand t...
Source: Amgen News Release - October 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies
THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores (nano-scale holes made by proteins contained within a synthetic membrane) in combination with electronics to perform direct, real-time sequencing of DNA and RNA. The technolo...
Source: Amgen News Release - October 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news